Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316998 | 0.91 | MAPK14 (0.35) | CETPMAPK14KDM4EMAPTMAPK1 | |
| SCHEMBL2359381 | 0.90 | MAPK14 (0.36) | CETPMAPK14GCGRJMJD6KDM4E | |
| SCHEMBL2315677 | 0.90 | MAPK14 (0.34) | CETPMAPK14GCGRJMJD6KDM4E | |
| SCHEMBL2316266 | 0.88 | MAPK14 (0.33) | CETPMAPK14GCGRJMJD6KDM4E | |
| SCHEMBL14719370 | 0.88 | MAPK14 (0.33) | CETPMAPK14KDM4EMAPK1ALDH1A1 | |
| SCHEMBL17836520 | 0.87 | PPARG (0.34) | CETPMAPK14MAPK1PPARGPPARD | |
| SCHEMBL2317914 | 0.85 | MAPK14 (0.34) | CETPMAPK14GCGRKDM4EMAPT | |
| SCHEMBL14108522 | 0.84 | MAPK1 (0.37) | MAPK14KDM4EMAPTMAPK1NPSR1 | |
| SCHEMBL2358155 | 0.83 | MAPK14 (0.39) | CETPMAPK14GCGRKDM4EMAPT | |
| SCHEMBL2315315 | 0.82 | BRAF (0.37) | MAPK14KDM4EMAPTMAPK1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | claimed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | claimed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | claimed |
| EP-2528909-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092088-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-08-04 | — | — | WO | claimed |
| EP-2528909-B1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-06-22 | — | — | EP | disclosed |
| US-8791265-B2 | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-29 | — | — | US | disclosed |
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) | 2013-02-28 | — | — | US | disclosed |
| EP-2528909-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092088-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053419-A1 | SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K15, MAP3K19, CDK3 | CETP 4240/4885MAPK14 36/4885GCGR 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.